Navigation Links
Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Date:5/9/2011

ts XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing of the milestone payments from Pfizer; Pfizer's ability to commercialize XIAPEX for Dupuytren's contracture in EU and Eurasian markets; the timing or likelihood of additional launches of XIAPEX in other EU and Eurasian markets and our receipt of any applicable milestone payments from Pfizer; Asahi Kasei Pharma's ability to develop, register for approval and commercialize XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan; the timing of reporting of results from the phase III trial for XIAFLEX for the treatment of Peyronie's disease; the Company's expected financial performance in 2011; products in development for Dupuytren's contracture and Frozen Shoulder syndrome; and the potential for XIAFLEX to be used in multiple indications.  


'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
9. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
10. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 LC Sciences LLC, a ... today that it is seeking beta testers for ... PCR based targeted sequencing technology. The system offers ... enables accurate detection of rare variants. It utilizes ... The company will collaborate with beta testers to ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Cytokinetics, Incorporated ... report first quarter results on Thursday, April 30, 2015 ... senior management will host a conference call at 4:30 ... and the company’s outlook for the future. , The ... accessed from the homepage and in the Investor Relations ...
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, ... announced its U.S. joint venture with G-treeBNT (ReGenTree ... phase 3 clinical trial for the orphan disorder, ... trial for dry eye syndrome (DES) in the ... eye drops, RGN-259/GBT201, this year.  Each of these ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: ... second quarter financial results on Thursday, August 6, 2009. OncoGenex ... p.m. EDT that afternoon to discuss quarterly results. , The ... the OncoGenex Web site at www.oncogenex.com . Alternatively, you ...
... ... Training Programme (JWTP) in India from October 6-10, 2009" is all set ... Jatropha and other Oil Crop Projects, Programmes and Priorities to Feed Biodiesel ... last year,s event, and a number of alternative feedstocks emerged over the ...
... ... MicroFuelerTM Installation , ... CA (PRWEB) August 1, 2009 -- The future of filling up your tank at home ... into a high performance ethanol fuel for cars was installed Thursday night at a home ...
Cached Biology Technology:Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 2Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 3Global Jatropha Hi-Tech Agricultural Training Programme (JWTP) 4America's Organic Home-Fueling Movement Begins in Los Angeles 2America's Organic Home-Fueling Movement Begins in Los Angeles 3
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... advocates will gather at Arizona State University for the ... 16-18, 2011. The conference will be a premier ... new approach to battling cancer: the development of ... disease. Despite 40 years since the "War on ...
... (IOF) and the World Health Organization Collaborating Centre for Metabolic ... launch of a FRAX calculator for Singapore. The ... been developed by the WHO to help evaluate patients at ... clinical risk factors, with or without the use of bone ...
... a major cause of plant diseases and are responsible ... other cereals all over the world. Together with scientists ... the Max Planck Institute for Terrestrial Microbiology in Marburg, ... University of Gttingen, analysed the genetic make-up of Sporisorium ...
Cached Biology News:Experts converge at Arizona State University for first preventive cancer vaccine conference 2WHO Fracture Risk Assessment Tool (FRAX) newly released for Singapore 2Evolutionary arms race between smut fungi and maize plants 2Evolutionary arms race between smut fungi and maize plants 3
Viral CCI Biotinylated Affinity Purified PAb...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Biology Products: